Subjective cognitive decline domain improves accuracy of plasma Aβ42/Aβ40 for preclinical Alzheimer's disease diagnosis: The SILCODE study

Documenti analoghi

• Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia
  di: Vasilios C. Constantinides, et al.
  Pubblicazione: (2023-01-01)
• Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice
  di: George P. Paraskevas, et al.
  Pubblicazione: (2022-12-01)
• Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
  di: Efstratios-Stylianos Pyrgelis, et al.
  Pubblicazione: (2023-11-01)
• CSF Extracellular Vesicle Aβ42 and Tau/Aβ42 Ratio Are Associated with Cognitive Impairment in Older People with HIV
  di: Debjani Guha, et al.
  Pubblicazione: (2023-12-01)
• Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
  di: Caterina Motta, et al.
  Pubblicazione: (2023-08-01)